ASX:NOX
Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report

Media

30-Apr-2021

Proactive Investors reported, "Noxopharm welcomes prestigious scientific journal reporting success of Veyonda® as booster of chemotherapy in late-stage cancer patients"

Read more here.

22-Apr-2021

TrialSiteNews reported, "Noxopharm Files Septic Shock Treatment Patent for Veyonda®"

Read more here.

17-Apr-2021

SBS online reported, "Hope for men with advanced prostate cancer after Australian treatment trials".

Read more here.

14-Apr-2021

THE WALL STREET JOURNAL reported, "Noxopharm Files Septic Shock Treatment Patent for Veyonda(R)"

Read more here.

14-Apr-2021

American Pharmaceutical Review presented, "Noxopharm Files Septic Shock Treatment Patent for Veyonda®"

Read more here.

6-Apr-2021

proactive reported, "Noxopharm files patent for Veyonda® as treatment for septic shock."

Read more here.

22-Mar-2021

Australian digital pharmaceutical news site, Health Industry Hub reported, "Noxopharm and BMS immuno-oncology trial proceeds to patient recruitment"

Read more here.

23-Feb-2021

In its conference data report for the ASCO Genitourinary Cancers Symposium, BioWorld reported on Noxopharm.

Read more here.

12-Feb-2021

Bloomberg Business reported, “Noxopharm Shares Major Cancer Survival Benefit at ASCO Global Conference”.

Read more here.